Emmaus Life Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

SELECTED FINANCIAL STATEMENT CAPTIONS - ASSETS

SELECTED FINANCIAL STATEMENT CAPTIONS - ASSETS

9 Months Ended

Sep. 30, 2021

Balance Sheet Related Disclosures [Abstract]

SELECTED FINANCIAL STATEMENT CAPTIONS - ASSETS

NOTE 4 — SELECTED FINANCIAL STATEMENT CAPTIONS - ASSETS

Inventories consisted of the following (in thousands):

	September 30, 2021			December 31, 2020
Raw materials and components	$	1,472		$	1,486
Work-in-process		70			721
Finished goods		6,317			6,064
Inventory reserve		(1,607	)		(1,184	)
Total	$	6,252		$	7,087

Prepaid expenses and other current assets consisted of the following (in thousands):

	September 30, 2021		December 31, 2020
Prepaid insurance	$	167	$	388
Prepaid expenses		242		454
Due from equity method investee		579		376
Other current assets		250		267
Total	$	1,238	$	1,485

Property and equipment consisted of the following (in thousands):

	September 30, 2021			December 31, 2020
Equipment	$	339		$	347
Leasehold improvements		39			39
Furniture and fixtures		102			99
Total property and equipment		480			485
Less: accumulated depreciation		(383	)		(365	)
Property and equipment, net	$	97		$	120

During the three months ended September 30, 2021 and 2020, depreciation expenses were approximately $11,000 and $12,000, respectively. During the nine months ended September 30, 2021 and 2020, depreciation expenses were approximately $34,000 and $35,000, respectively.